Corporate History

1. Early Years

1977: IDS is established as RIA UK Limited
1982: IDS functions of product development, manufacturing, product support and distribution are established
1990: Headquarters in Boldon open


2. Pioneering Calcium Metabolism

1995: IDS launches the first 1,25 vitamin D product in the European and Japanese markets
1998: IDS launches the first 25D RIA product
1999: IDS receives a Queen’s Award for Technical Achievement


3. Expanding Into International Markets

2003: IDS Inc., Arizona USA established
2004: IDS GmbH, Frankfurt, Germany established
2005: IDS S.A. Paris, France established
2006: IDS receives a Queen’s Award for the second time, in International Trade
2007: IDS opens research and production facilities in Liege, Belgium and Pouilly, France


4. Automation and Portfolio Expansion

2007: IDS acquires automated immunoassay platform
2009: Launch of automated 25D
2009: IDS launches its first fully-automated bone product IDS-iSYS PINP and growth product IDS-iSYS human Growth Hormone (hGH)
2010: IDS launches 3 newly developed, fully-automated assays:

  • Parathyroid hormone (PTH) calcium biomarker
  • Insulin-like Growth Factor 1 (IGF-1)
  • Osteocalcin bone protein

2012: Patrik Dahlen is appointed CEO

2013: US FDA grants clearance for 1,25-dihidroxy vitamin D assay for use on the IDS-iSYS system


5. Re-defining our Strategy – Focus on Endocrinology Specialty Assays

2013: IDS enters the Chinese and Brazilian markets
2014: IDS is focused on developing an endocrinology specialty menu
2014: IDS works with partners to develop assay panels in complementary fields
2014: IDS acquires DiaMetra S.r.l, (DiaMetra) as part of this new strategy
2015: Patricio Lacalle is appointed CEO to lead the company’s renewed strategy